# Clinical Performance Objectives in Immunology Department of Medical and Research Technology University of Maryland School of Medicine

Upon completion of the **Clinical Immunology** rotation, the MLS student will be able to:

# I. <u>Specimen Handling and Processing/Laboratory Safety</u>

- 1. Following departmental protocol, demonstrate safe work practices by:
  - a. Wearing personal protective equipment (PPE) as required.
  - b. Handling and disposing of contaminated materials according to standard precautions.
  - c. Handling chemicals according to safety procedures.
- 2. State the specimen collection and handling requirements for each immunologic test.
- 3. Evaluate patient specimens for acceptability, using laboratory policy.
- 4. If patient specimens are determined to be unacceptable, state the resolution.

## II. QUALITY CONTROL AND QUALITY ASSURANCE

- 1. Prepare controls and reagents within acceptable QA limits.
- 2. Using established criteria, determine whether or not available controls and reagents are acceptable for use according to lab protocol.
- 3. Recognize all critical values obtained during patient testing as abnormal.
- 4. Report critical values immediately to clinical instructor.
- 5. State the confidentiality policy of the facility during testing procedure and reporting in accordance with HIPAA guidelines.
- 6. Observe basic laboratory computer applications where relevant.
- 7. Review quality control data for a minimum of **three** (3) different immunology assays performed in the laboratory.
- 8. Evaluate quality control data according to established laboratory guidelines.
- 9. Discuss appropriate actions for unacceptable control results.

#### III. CORE KNOWLEDGE AND SKILLS

- 1. Demonstrate pipetting technique in accordance with manufacturers' instructions using all available types of pipettes.
- 2. Pipette reagents and samples accurately.
- 3. Calculate all specimen dilution concentrations with 100% accuracy.
- 4. To the satisfaction of the clinical instructor:
  - a. Explain how to correctly calculate both serial and non-serial dilutions.
  - b. Explain the concept of lattice theory in antigen/antibody reactions: prozone, equivalence, post zone (and how that might impact patient test results).
  - c. Determine corrective action that is needed upon recognizing when prozone has occurred.
  - d. Discuss the five classes of human immunoglobulins in terms of physical structure, biological activity and location(s).
  - e. Compare and contrast primary and secondary immune responses
  - f. Define the functions of the following cell types in regard to their role(s) in the humoral or cellular immune systems: neutrophil, monocyte, macrophage, eosinophil, basophil, B lymphocyte, T<sub>H</sub> lymphocyte, T<sub>C</sub> lymphocytes and NK cells.
  - g. Compare and contrast the terms sensitivity and specificity.

#### IV. IMMUNOLOGY ASSAY METHODOLOGIES/INSTRUMENTS

- 1. Discuss the theories/principles of operation of the following assays:
  - Latex agglutination
  - Hemagglutination
  - immunodiffusion
  - Direct immunofluorescence
  - Indirect immunofluorescence
  - ELISA (EIA) sandwich technique
  - Western blot
  - FPIA
  - RIA
  - Flow cytometry
- 2. Identify the common immunological application of the: fluorometer, chemiluminometer, photometer and fluorescence microscope.

- 3. Perform if available, the following assays to the satisfaction of the clinical instructor: Latex agglutination, Hemagglutination, EIA.
- 4. Observe, if available on site, the following assays: Immunodiffusion, Direct and indirect immunofluorescence, FPIA, RIA, Flow cytometry.

# V. BACTERIAL SEROLOGY: NON TREPONEMAL (VDRL, RPR) TREPONEMAL (FTA-ABS), STREPTOZYME, LYME DISEASE

- 1. To the satisfaction of the clinical instructor:
  - a. Discuss the theory/principle of each test.
  - b. Correlate the disease manifestations with expected test results for each assay.
  - c. Explain the significance of reactive, weakly reactive and non-reactive results in the RPR test.
  - d. Discuss instances where false positive and false negative RPR and FTA-ABS reactions might be expected to occur.
  - e. Perform RPR assay QC/calibration techniques (temperature, needle, rotator) according to lab protocol.
  - f. Interpret with 100% accuracy a minimum of **10** RPR screening tests.
  - g. Perform a minimum of  $\underline{2}$  RPR titers on previously reactive specimens, matching the technologist's results within  $\pm$ 0 one dilution factor.
  - h. Compare & contrast the RPR and FTA-ABS assays for syphilis in terms of sensitivity, specificity, use in diagnosis, and use in monitoring therapy.
  - i. Discuss or perform the Streptozyme assay on a minimum of **2** specimens.
  - j. Discuss or perform the screening and/or confirmatory western blot for Lyme Disease on a minimum of two (2) specimens.

#### VI. VIRAL SEROLOGY - HEPATITIS A-C, EBV, HIV, RUBELLA, CMV, HERPES

- 1. Correlate viral markers with clinical disease for the following: Hepatitis A, B, C; EBV; HIV; Rubella; CMV.
- 2. List the viral markers used to screen blood donor units.
- 3. Discuss or perform a hepatitis assay.
- 4. Explain the theory/principle of screening tests for infectious mononucleosis.
- 5. Perform a minimum of **five (5)** screening tests for infectious mononucleosis, matching the technologist's results with 100% accuracy.
- 6. Observe or discuss an HIV antibody screen.
- 7. Discuss how ELISA and Western blot tests are used to diagnose HIV infection.

8. Discuss the TORCH panel with regard to its use and clinical significance.

## VII. AUTOIMMUNITY ASSAYS – ANA, CRP, C3, C4, RF, THYROID ANTIBODIES

- 1. Observe, perform or discuss the following:
  - ANA assay (both fluorescence and enzyme methods)
  - CRP
  - C3
  - C4
  - RF
  - Thyroid antibodies
- 2. When given electronic imagess or slides, visually identify the following ANA patterns: homogeneous, peripheral (rim) speckled, nucleolar, and centromere.
- 3. When given electronic images or slides, correlate the ANA patterns seen with the following disease states: SLE, Sjögrens Syndrome, Mixed Connective Tissue Disease (MCTD), Progressive Systemic Sclerosis (Scleroderma) and CREST Syndrome.
- 4. If available on site, resolve technical, instrument, and/or physiologic causes of problems or unexpected test results for each assay performed to the satisfaction of the clinical instructor.